Chapter 93
Approach to Pancytopenia in the ICU

93.1 Introduction

Pancytopenia, characterized by the simultaneous reduction of hemoglobin, neutrophils, and platelets below critical levels, is a significant clinical concern in the ICU. It reflects a broad spectrum of pathophysiological processes ranging from bone marrow suppression to peripheral destruction of blood elements. Effective management requires a systematic approach to diagnosis and treatment, as the causes can range from nutritional deficiencies to life-threatening conditions like disseminated intravascular coagulation (DIC) or hemophagocytic lymphohistiocytosis (HLH). This chapter provides a comprehensive approach to pancytopenia in critically ill patients, incorporating advanced diagnostic tools, management strategies, and considerations for special populations and emerging conditions [1, 2] [Ref: Algorithm 93.1].

93.2 Criteria

The following thresholds define Pancytopenia:

- Hemoglobin: <10 g/dL.
- Absolute neutrophil count (ANC): <1500/μL.
- Platelet count: <100,000/μL.

These thresholds should prompt immediate investigation to determine the underlying cause, especially in the ICU where patients are vulnerable to rapid deterioration.

S. B. Mishra et al., *Mastering ICU Care*,
https://doi.org/10.1007/978-981-95-0179-3_93

93.3 Etiological Classification

A thorough understanding of the potential causes is essential for effective management. The etiologies can be broadly classified into inherited syndromes, acquired conditions, nutritional deficiencies, autoimmune processes, infections, and other systemic diseases.

Inherited Syndromes
- Fanconi Anemia: A genetic disorder leading to bone marrow failure, congenital anomalies, and increased cancer risk.
- Dyskeratosis Congenita: A telomere maintenance disorder causing bone marrow failure, skin abnormalities, and pulmonary fibrosis.

Acquired Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH): A stem cell disorder causing hemolysis, thrombosis, and bone marrow failure.
- Myelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders leading to ineffective hematopoiesis and risk of transformation to acute myeloid leukemia.
- Aplastic Anemia: Immune-mediated destruction of hematopoietic stem cells resulting in pancytopenia.

Nutritional Deficiencies
- Vitamin B12 and Folate Deficiency: Lead to megaloblastic anemia characterized by macrocytic red blood cells and ineffective erythropoiesis.
- Copper Deficiency: Causes neutropenia and anemia due to impaired hematopoiesis.
- Zinc Toxicity: Excess zinc interferes with copper absorption, leading to secondary copper deficiency and cytopenias.

Autoimmune Processes
- Systemic Lupus Erythematosus (SLE): Autoantibody-mediated destruction of blood cell lines.
- Felty's Syndrome: A triad of rheumatoid arthritis, neutropenia, and splenomegaly resulting in increased peripheral destruction.

Infections
- Sepsis and Cytokine Storms: Lead to bone marrow suppression and increased peripheral destruction.
- Viral Infections: Such as HIV, EBV, and emerging viruses like SARS-CoV-2 (COVID-19), can cause bone marrow suppression and cytokine-induced damage.

Hypersplenism
- Portal Hypertension: Causes splenomegaly and sequestration of blood cells.
- Infiltrative Diseases: Such as sarcoidosis or malignancies leading to splenic enlargement and cytopenias.

Hemophagocytic Lymphohistiocytosis (HLH)

- HLH: A life-threatening hyperinflammatory syndrome characterized by excessive activation of macrophages and cytotoxic T cells, leading to hemophagocytosis and pancytopenia.

HLH should be considered in patients with unremitting fevers and hyperferritinemia. The probability of HLH can be calculated via the H-score.

Iatrogenic

Chemotherapy, radiotherapy, antibiotics such as chloramphenicol, trimethoprim, and linezolid. Other medications like azathioprine, methotrexate, carbamazepine, and valproate.

Geographic and Epidemiological Variations

- Megaloblastic Anemia in South Asia: Higher prevalence due to dietary habits and malnutrition.
- Infectious Causes in Endemic Areas: Such as malaria, leishmaniasis, and certain viral infections contributing to pancytopenia.

93.4 Initial Workup

The patient's medical history should be thoroughly reviewed to identify potential causes of the disease. This includes evaluating symptoms such as fever, night sweats, weight loss, jaundice, fatigue, recurrent bleeding, and infections. A past history of drug or toxin exposure should be taken to investigate iatrogenic causes of pancytopenia. Travel history may indicate a tropical infection leading to hypersplenism. Physical examination should include assessment for lymphadenopathy, hepatomegaly, or splenomegaly.

The diagnostic workup aims to distinguish between central (bone marrow) and peripheral causes of pancytopenia. Early identification is crucial in the ICU to prevent rapid deterioration.

Complete Blood Count (CBC)

- Quantifies Cytopenias: Determines the severity and combination of low cell lines.
- Mean Corpuscular Volume (MCV): Assesses for macrocytosis or microcytosis, suggesting nutritional deficiencies or hemoglobinopathies.

Peripheral Blood Smear

- Cell Morphology: Identifies abnormal shapes, sizes, or inclusions in blood cells.
- Blasts and Dysplastic Cells: Suggestive of leukemias or MDS.
  Schistocytes: Indicate microangiopathic hemolytic anemia.

Reticulocyte Count

- Bone Marrow Activity: Low reticulocyte count suggests decreased production; high count indicates peripheral destruction or hemolysis.

Bone Marrow Examination
- Aspiration and Biopsy: Essential for diagnosing bone marrow disorders, infiltrative diseases, or malignancies.
- Cytogenetics and Flow Cytometry: Provide detailed information on cell lineage and genetic abnormalities.

Advanced Diagnostic Tools
- Next-Generation Sequencing (NGS): Detects genetic mutations associated with MDS, HLH, and inherited bone marrow failure syndromes.
- Molecular Diagnostics: Identify specific gene mutations (e.g., TP53, RUNX1) guiding prognosis and therapy.
- Immature Platelet Fraction (IPF) or Reticulated Platelet Count: Differentiate between decreased production and increased destruction of platelets.

93.5 Pathophysiological Insights

Autoimmune Processes
- Mechanism: Autoantibodies target blood cell antigens leading to their destruction.
- SLE: Autoantibodies against nuclear components cause complement-mediated lysis of cells.
- Treatment Implications: Immunosuppressive therapies reduce antibody production and inflammation.

Sepsis and Cytokine Storms
- Impact on Hematopoiesis: Pro-inflammatory cytokines suppress bone marrow function.
- Peripheral Destruction: Activation of the coagulation system and endothelial damage lead to consumption of blood cells.
- Critical Care Context: Management controls infection and modulates the immune response.

93.6 Management

Effective management involves supportive care and addressing the underlying cause.

Supportive Care
- Transfusion Thresholds:
- Hemoglobin: Maintain above 7 g/dL in stable patients; higher thresholds for those with cardiovascular disease.
- Platelets: Transfuse when <10,000/μL or < 20,000/μL if febrile or bleeding risk is high.
- Infection Management:

- Empirical Antibiotics: Early initiation in neutropenic fever.
- Antifungal and Antiviral Prophylaxis: Consider in prolonged neutropenia.
- Growth Factors:
- G-CSF: Stimulates neutrophil production in neutropenia.
- Thrombopoietin Receptor Agonists: Eltrombopag promotes platelet production, especially in aplastic anemia.

Targeted Therapies
- Aplastic Anemia:
- Immunosuppressive Therapy: Combination of antithymocyte globulin (ATG) and cyclosporine.
- Eltrombopag: Enhances hematopoiesis in refractory cases.
- Autoimmune Cytopenias:
- Corticosteroids: First-line therapy to reduce immune-mediated destruction.
- Rituximab: Monoclonal antibody against CD20 for steroid-refractory cases.
- Advanced Immunomodulatory Therapies: Such as azathioprine or mycophenolate mofetil.
- Myelodysplastic Syndromes (MDS):
- Hypomethylating Agents: Azacitidine or decitabine improve blood counts and delay progression.
- Lenalidomide: Effective in del(5q) MDS subtype.
- Hemophagocytic Lymphohistiocytosis (HLH):
- HLH-94 Protocol: Dexamethasone and etoposide-based regimen.
- Emerging Therapies: Targeted treatments like emapalumab (an interferon-gamma blocker).

Interventions for Refractory Cases
- Hematopoietic Stem Cell Transplantation (HSCT):
- Curative Potential: Especially in inherited bone marrow failure syndromes and severe aplastic anemia.
- Considerations: Patient's age, comorbidities, and availability of a suitable donor.
- Splenic Embolization or Splenectomy:
- Indications: Hypersplenism causing severe cytopenias unresponsive to medical therapy.
- Risks: Post-splenectomy infections; prophylactic vaccinations recommended.

Special Populations

Pediatric Patients
- Distinct Presentations: Higher likelihood of inherited syndromes like Fanconi anemia or dyskeratosis congenita.
- Management Considerations:
- Genetic Counseling: For family planning and risk assessment.
- Growth and Development Monitoring: Addressing endocrine and developmental issues.

- HSCT: Often considered earlier due to the progressive nature of inherited disorders.

Elderly Patients
- Myelodysplastic Syndromes Prevalence: Increases with age.
- Comorbidities: Affect treatment choices and tolerability.
- Management Strategies:
- Less Intensive Therapies: Adjusted doses of hypomethylating agents.
- Supportive Care Focus: Quality of life and symptom management.

Supportive Care Protocols in the ICU

Transfusion Strategies
- Individualized Thresholds: Based on patient's hemodynamic status, bleeding risk, and comorbidities.
- Leukoreduced and Irradiated Blood Products: Reduce the risk of transfusion reactions and graft-versus-host disease.

Infection Management
- Neutropenic Precautions: Protective isolation, strict hand hygiene.
- Empirical Antimicrobials: Broad-spectrum antibiotics initiated promptly.
- Antifungal and Antiviral Agents: For high-risk patients.

Organ Support
- Renal Replacement Therapy: If acute kidney injury develops due to sepsis or HLH.
- Mechanical Ventilation: For respiratory failure, often complicated by infections or pulmonary hemorrhage.

93.7 Emerging Conditions and Contexts

COVID-19 and Other Viral Pandemics
- Bone Marrow Suppression: Direct viral effects or immune-mediated damage leading to cytopenias.
- Cytokine Storms: Exacerbate pancytopenia and require immunomodulatory therapies.
- Management:
- Antiviral Treatments: As per evolving guidelines.
- Immunotherapies: Tocilizumab (IL-6 inhibitor) used in cytokine release syndrome.

Sepsis-Induced Pancytopenia

- Pathophysiology: Overwhelming infection leads to bone marrow suppression and increased consumption.
- Therapeutic Apheresis: Considered in severe cases of hyperinflammation.

93.8 Conclusion

The approach to pancytopenia in the ICU necessitates a comprehensive and systematic evaluation to identify the underlying cause promptly. Incorporating advanced diagnostic tools like NGS and molecular diagnostics enhances the accuracy of diagnoses such as MDS and HLH. Understanding the pathophysiological mechanisms, particularly in autoimmune processes and cytokine storms, guides targeted therapy.

Management strategies should be refined to include targeted therapies like eltrombopag for aplastic anemia and advanced immunomodulatory treatments for autoimmune cytopenias. Interventions for refractory cases, including hematopoietic stem cell transplantation and splenic embolization, should be considered.

Special attention is required for pediatric and elderly populations, acknowledging their distinct presentations and management needs. Additionally, emerging conditions like COVID-19 necessitate adaptability in management approaches due to their impact on bone marrow function.

Early intervention with appropriate supportive care protocols, tailored for ICU patients—including transfusion thresholds and infection management strategies—is critical. A structured algorithm ensures systematic assessment and guides appropriate interventions, ultimately improving patient outcomes in this critical setting.

Algorithm 93.1: Approach to pancytopenia in the ICU



Bibliography

1. Gnanaraj J, Parnes A, Francis CW, Go RS, Takemoto CM, Hashmi SK. Approach to pancytopenia: diagnostic algorithm for clinical hematologists. Blood Rev. 2018;32(5):361–7.
2. Chew S, Kamangar M. Approach to pancytopenia: from blood tests to the bedside. Clin Med (Lond). 2024;24(5):100235.